In a meta-analysis of 18,282 patients from 52 randomized controlled trials, patients receiving VEGFR-TKIs were compared with patients not treated with these drugs.[4] The RRs for high-grade liver enzyme elevations were 1.66, 1.61, 1.02, and 1.34, respectively, and the incidence of hepatic failure with VEGFR-TKI was 0.8% overall. The gene discussed is KDR; the disease is liver failure.